Buy ARA-290 Peptide

ARA-290 is a nonerythropoietic peptide derived from erythropoietin, designed to improve metabolic control and alleviate neuropathic symptoms, particularly in patients with type 2 diabetes. It shows promise in preventing peripheral nerve injury-induced neuropathic pain and offers long-term relief by targeting the innate repair receptor. Additionally, ARA-290 has been studied for its potential benefits in improving quality of life for patients with conditions like sarcoidosis.

Sale!
ARA-290 Pre-Mixed Pen
£11.87 – £38.97 Select options This product has multiple variants. The options may be chosen on the product page
Sale!
ARA-290 Peptide Vial 2mg
£9.29 – £18.27 Select options This product has multiple variants. The options may be chosen on the product page
Sale!
ARA-290 Nasal Spray
£17.29 – £29.58 Select options This product has multiple variants. The options may be chosen on the product page

Which ARA-290 Product is Right for You?

PharmaGrade Store Italy supplies a number of ARA-290 peptide products to suit your research objectives:

- ARA-290 Peptide Vial – packaged in a sterile, glass vial ready for reconstitution. Please note you also require bacteriostatic water for peptide reconstitution.
  Available in 2mg peptide vials.
- ARA-290 Nasal Spray – a pre-mixed, ready to use ARA-290 solution for the administration into the nasal passage of clinical research participants. Choose from 15ml or 30ml nasal sprays here.
- ARA-290 Pre-Mixed Peptide Pen – Peptide pen kits and cartridges come pre-mixed with ARA-290 peptide and bacteriostatic water. Buy ARA-290 2mg Pre-Mixed Pen here.

Buy ARA-290 for Clinical Research Use

ARA-290 is a nonerythropoietic peptide derived from erythropoietin [1]. Sometimes called Cibinetide, it is designed to improve metabolic control and alleviate neuropathic symptoms, particularly in type 2 diabetes patients. Unlike erythropoietin, ARA-290 does not stimulate red blood cell production, which reduces potential side effects [1].

Its mechanism of action involves targeting the innate repair receptor, providing long-term relief of neuropathic pain. ARA-290 shows promise in preventing peripheral nerve injury-induced neuropathic pain and has potential applications in conditions such as sarcoidosis [2].

Furthermore, ARA-290 has been reported to have a significant change in the symptoms and increase corneal nerve fiber density in affected patients. This suggests that ARA-290 could be beneficial in treating neuropathic pain and potentially aiding in nerve repair or regeneration.

By improving quality of life and managing pain, ARA-290 represents a significant advancement in therapeutic interventions for these conditions.

Benefits of ARA-290 Italy

cnItaly Clinical studies and in vitro testing have suggested that ARA-290 peptide could have the following potential benefits:

ARA-290 improves metabolic control for Type 2 Diabetes patients – ARA-290 helps individuals living with Type 2 Diabetes [3].
Reduces nerve pain – ARA-290 could be used in the treatment of neuropathic pan. It alleviates neuropathic symptoms by targeting the innate repair receptor, providing relief from chronic neuropathic pain caused by tissue injury [4].
Provides relief for sarcoidosis – ARA-290’s ability to modulate repair processes and reduce inflammatory responses can be beneficial for those with sarcoidosis [2].
Enhances nerve repair – ARA-290 has shown promise in addressing nerve fibre loss, particularly in conditions like sarcoidosis-associated small nerve fiber loss.

Scientific Research ARA-290 Italy

Italy Clinical research on ARA-290 peptide has shown promising results, particularly in reducing neuropathic pain and enhancing metabolic control. Studies highlight its efficacy among patients with type 2 diabetes and sarcoidosis, demonstrating significant improvements in managing chronic pain and metabolic conditions [2] [4].

The peptide works by targeting the innate repair receptor, a mechanism that helps modulate pain and inflammation pathways [5]. This targeted action not only alleviates pain but also supports overall metabolic health, making it a valuable therapeutic option for complex conditions.

Recent studies of patients during Italy clinical trials have underscored the effects of ARA-290’s safety profile, with minimal serious side effects reported. Long-term benefits observed in previous studies include sustained pain relief and improved quality of life, emphasizing its potential as a treatment modality [6]. The ability of ARA-290 to engage specific receptors with precision allows it to mitigate symptoms effectively, paving the way for future studies in diverse therapeutic areas.

ARA-290 Specifications:

View PharmaGrade Store Italy ARA-290 HPLC Certificate here.

Amino Acid Sequence: XEQLERALNSS

Molecular Formula:C51H84N16O21

Molecular Weight:1257.3 g/mol

Buy ARA-290 Italy online from PharmaGrade.Store today!

Frequently Asked Questions about ARA-290 Italy

What is Sarcoidosis?

Sarcoidosis is an inflammatory disease characterized by the formation of tiny lumps or nodules, known as granulomas, in various organs of the body, including the lungs, lymph nodes, skin, and eyes. The exact cause of sarcoidosis is unknown, but it is believed to involve an immune response to certain triggers, such as infections or environmental factors. Symptoms can vary widely depending on the organs affected, and the condition can sometimes resolve on its own or require treatment to manage symptoms and prevent complications [7].

How can ARA-290 aid tissue repair?

ARA-290 can aid in tissue damage repair by targeting the innate repair receptor. This receptor plays a crucial role in managing inflammation and promoting tissue healing. By binding to this receptor, ARA-290 helps reduce inflammation, which is often a barrier to effective tissue repair. This allows the body to focus on regenerating damaged cells and tissues more efficiently. By binding to the innate repair receptor experimental study suggests ARA-290 can reduce inflammation, which is crucial in managing injuries involving the spinal cord. Results of these studies have shown that ARA-290 can enhance tissue regeneration, offer tissue protection and accelerate healing processes, making it a promising therapeutic option for those experiencing tissue damage.

Can ARA-290 have any benefit to Diabetes patients?

A current study has suggested that ARA-290 may have potential benefits for individuals with diabetes, particularly type 2 diabetes. It has been reported to make a positive significant difference metabolic control and alleviate neuropathic symptoms in patients [8]. Additionally, studies on the treatment group have indicated that ARA-290 can enhance glucose tolerance and insulin release in diabetic models. These findings suggest that ARA-290 may be a promising candidate for managing certain aspects of diabetes, although further clinical evaluation is warranted to investigate any adverse effects.

Blogs:

Top Pain Relieving Peptides

This blog explores the potential of pain-relieving peptides as a promising advancement in pain management. It highlights how these peptides interact with the body’s natural pain pathways, offering targeted relief with fewer side effects compared to traditional painkillers. Various peptides, such as Melanotan II and ARA-290, which target specific receptors to modulate pain signals and reduce inflammation are also discussed. These peptides are particularly beneficial for managing chronic pain conditions like fibromyalgia and arthritis.

Discover more about using peptides for pain relief

Metabolism Management Peptides

This blog discusses the use of MOTS-c peptide and its potential role in metabolism management. MOTS-c, a mitochondrial-derived peptide, is gaining attention for its ability to enhance glucose uptake and regulate energy expenditure, which may help combat insulin resistance and support weight management. The blog also explores how peptides like ARA-290 and MOTS-c have a vital role in the future development of promising applications in treating metabolic disorders like type 2 diabetes and obesity.

Scientific Research:

[1] Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10925-30.

[2] van Velzen M, Heij L, Niesters M, Cerami A, Dunne A, Dahan A, Brines M. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs. 2014 Apr;23(4):541-50.

[3] Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015 Mar 13;20(1):658-66.

[4] Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, Cerami A, Dahan A. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014 Feb 16;10:13.

[5] Zhang W, Yu G, Zhang M. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides. 2016 Feb;76:73-9.

[6] Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012 Nov 15;18(1):1430-6.

[7] Cong Chen, Nanzhi Luo, Fuqiang Dai, Wenjing Zhou, Xiaoqing Wu, Jian Zhang, Advance in pathogenesis of sarcoidosis: Triggers and progression, Heliyon, Volume 10, Issue 5, 2024.

[8] Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015 Mar 13;20(1):658-66.

Buy ARA-290 Italy Today from PharmaGrade.Store

ALL PRODUCT INFORMATION AND ARTICLES ON THIS SITE ARE FOR EDUCATIONAL PURPOSES ONLY

DISCLAIMER: All products sold by PharmaGrade.Store are for research and laboratory use only. These products are not designed for use or consumption by humans or animals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such. By purchasing from our Website the buyer accepts and acknowledges the risks involved with handling of these products. All articles and product information provided on this Website are for informational and educational purposes only. Handling and use of these products should be restricted to suitably qualified professionals